Glaukos is transforming the treatment of chronic eye diseases
With the use of novel therapies, Glaukos provides sustainable solutions to important clinical needs.
Who We Are
Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease.
Our Mission
Innovation is at the core of everything we do. Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases.
Glaukos Corporate Overview
Founded in 1998, Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in the United States, Canada, United Kingdom, Germany, Japan, Australia and Brazil.
Empowering Ophthalmic Growth Worldwide
Timeline
-
Glaukos is founded
-
The first trabecular micro-bypass glaucoma stent is developed
-
The first human implant of micro-bypass glaucoma stent is performed
-
Landmark trial evaluating iStent® in conjunction with cataract surgery begins
-
Glaukos receives Category III CPT code to describe insertion of a flow device into the trabecular meshwork of the eye
-
Glaukos establishes a direct sales organization and launches iStent in the United States
-
Glaukos secures 100% Medicare coverage for the iStent® procedure
-
Glaukos establishes a direct sales organization and launches iStent inject® in Germany
-
Glaukos completes initial public offering
-
iStent® is approved in Japan
iStent® launches in Australia and Canada -
Glaukos expands into 17 countries with direct sales operations
-
iStent inject® is approved by the FDA in combination with cataract surgery; US commercial launch
-
- Glaukos acquires Avedro, establishing the cornerstone of a new corneal health franchise
- Glaukos acquires DOSE Medical, establishing a new R&D retinal program
- Glaukos enters licensing agreement with Intratus for a non-invasive, cream-based drug delivery platform
-
- iStent inject® W is launched
- The iLink® corneal cross-linking procedure is introduced to the Glaukos family
- Glaukos completes convertible debt financing
- Glaukos issues inaugural sustainability report
-
- Glaukos completes patient enrollment in Phase 3 clinical program for iDose TR
- Glaukos surpasses 200 peer-reviewed publications on iStent technologies
- Glaukos enters licensing agreement with Attillaps Holdings, Inc.
-
- U.S. commercial launch of iAccess and iStent infinite®
- Glaukos exceeds 1 million iStent devices implanted
- Commenced Phase 2 clinical program for iLution platform
-
- Glaukos receives FDA Approval for iDose® TR(travoprost intracameral implant), 75 mcg
- Glaukos commences first-in-human clinical development for retina program (GLK-401)
-
- iStent infinite EU MDR Certification
- Glaukos receives FDA Approval for Epioxa™ (riboflavin 5'-phosphate ophthalmic solution)
-
Glaukos exceeds 3 million iStent devices implanted
Looking Ahead At Glaukos
Glaukos is actively developing microsurgical devices, pharmaceuticals, and biosensors for the treatment of chronic eye disease. Stay tuned!
With direct sales operations in 17 countries, we employ more than 250 commercial sales personnel worldwide. And we serve additional international markets through relationships with valued distributors. In all, our technologies are currently approved for use in more than 30 countries, and we continue to pursue regulatory approvals in more regions.
Corporate Responsibility
Code of Conduct
This reflects our core values of integrity, transparency, and accountability—principles that guide both our internal operations and our engagement with the broader community.
View Here
Prioritizing Corporate
Responsibility
We’re proud of the corporate citizenship efforts of the Glaukos Charitable Foundation, Company and employees, and pledge to continue this important work in helping improve the lives of those suffering and in need.
About Glaukos Charitable FoundationCareers at Glaukos
Help put the next wave of disruptive technologies on the market.
Work with a team that’s dedicated to making a difference in the lives of patients worldwide.